Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited announced that its ESOP Allotment Committee approved the allotment of 53,500 equity shares to eligible employees under the Bliss GVS Pharma Limited – Employee Stock Option Plan 2019, increasing the company's issued, subscribed, and paid-up share capital from 10,63,30,473 equity shares aggregating Rs 10,63,30,473 to 10,63,83,972 equity shares aggregating Rs 10,63,83,972.

Bliss GVS Pharma Limited submitted a certificate to the National Stock Exchange of India Limited and BSE Limited under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, its Registrar and Share Transfer Agent.

Bliss GVS Pharma Limited will close its trading window for insiders, designated persons, and their immediate relatives starting October 1, 2026, and continuing until 48 hours after the announcement of the company’s unaudited financial results for the quarter and half year ended September 30, 2026, as per Securities Exchange Board of India regulations.

Bliss GVS Pharma Limited will hold a board meeting on Thursday, October 01, 2026, to consider and approve the establishment of a Senior Executive Employee Stock Option Plan 2026 and an Employee Stock Option Plan 2026, according to a regulatory filing.

Bliss GVS Pharma Limited announced the allotment of 55,250 equity shares with a face value of Re. 1 each to eligible employees under its Employee Stock Option Plan 2019, increasing the company’s issued, subscribed, and paid-up share capital from 10,62,75,223 equity shares aggregating Rs 10,62,75,223 to 10,63,30,472 equity shares aggregating Rs 10,63,30,472. The exercise price per share was Rs 43, with a premium of Rs 42, and the shares are subject to a lock-in period of six months until March 03, 2027.

Bliss GVS Pharma Limited announced that its ESOP Allotment Committee approved the allotment of 31,250 equity shares to eligible employees under the Bliss GVS Pharma Limited – Employee Stock Option Plan 2019, increasing the company’s issued, subscribed, and paid-up share capital from 10,62,43,973 equity shares aggregating Rs 10,62,43,973 to 10,62,75,222 equity shares aggregating Rs 10,62,75,222.

Bliss GVS Pharma Limited will hold a board meeting on Wednesday, August 12, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing. The trading window for designated persons and their immediate relatives was closed from July 1, 2026, and will remain closed until 48 hours after the announcement of the financial results.

Bliss GVS Pharma announced that the 41th Annual General Meeting(AGM) of the company will be held on 15 July 2026.

Bliss GVS Pharma announced that the Board of Directors of the Company at its meeting held on 12 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Bliss GVS Pharma rose 128.96% to Rs 35.58 crore in the quarter ended March 2026 as against Rs 15.54 crore during the previous quarter ended March 2025. Sales rose 29.80% to Rs 256.99 crore in the quarter ended March 2026 as against Rs 197.99 crore during the previous quarter ended March 2025. For the full year,net profit rose 53.18% to Rs 129.13 crore in the year ended March 2026 as against Rs 84.30 crore during the previous year ended March 2025. Sales rose 14.50% to Rs 927.11 crore in the year ended March 2026 as against Rs 809.73 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales256.99197.99 30 927.11809.73 15 OPM %17.2910.65 -17.6915.65 - PBDT53.5931.48 70 225.56155.06 45 PBT44.9223.44 92 192.08125.64 53 NP35.5815.54 129 129.1384.30 53 Powered by Capital Market - Live